A股異動 | 芭田股份漲7% 與全資子公司簽訂硝酸供應合作框架協議
格隆匯9月30日 | 磷化工板塊今日重拾升勢集體大漲,其中,芭田股份盤中漲7.36至6.71元,總市值約60億元。芭田股份9月29日發佈晚間公吿,近日,全資子公司貴州芭田與曲靖市德方納米科技有限公司簽署《硝酸供應合作框架協議》。協議生效後,由貴州芭田向曲靖市德方納米科技有限公司提供硝酸產品,協議期為2021年10月1日至2022年3月31日。國海證券發研報稱,公司是複合肥行業頭部企業,掌握優質磷礦資源,未來發展空間廣闊,與德方納米簽訂協議有望大幅度提升公司硝酸產能利用率和銷售量,顯著增厚公司利潤。該行首予芭田股份“買入”評級。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.